Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease

NCT01524887 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT01524887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01524887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Terminated
Start date
January 23, 2012
Completion date
July 16, 2013
Enrollment
508 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer´s disease